sponsored
PatientsVille.com Logo

PatientsVille

3% HYDROGEN PEROXIDE Medical Research Studies

Up-to-date List of 3% HYDROGEN PEROXIDE Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest 3% HYDROGEN PEROXIDE Medical Research Studies

Rank Status Study
1 Recruiting The Effects of Cyclosporin A in a Low Humidity Environment, on the Ocular Surface
Condition: Dry Eye
Interventions: Drug: Cyclosporin 0.05% emulsion;   Drug: Endura, Refresh artificial tears
Outcome Measures: Corneal fluorescein staining;   eye irritation symptoms
2 Recruiting Safety and Efficacy Study of SJP-0035 Ophthalmic Solution in Patients With Moderate to Severe Corneal Epithelial Disorders
Condition: Corneal Epithelial Disorders
Interventions: Drug: SJP-0035 Ophthalmic Solution;   Drug: Vehicle for SJP-0035 Ophthalmic Solution
Outcome Measures: Clearing of corneal fluorescein staining at week 4;   Number of Participants with Adverse Events as a Measure of Safety.;   Changes of subjective symptoms: blurred vision, photophobia and Eye Irritation;   Changes of subjective signs: tear stability, conjunctival epithelia, and surface curvature of cornea
3 Recruiting Effects of Conventional Dry Eye Treatments on the Ocular Surface Response to Low Humidity Environment in Patients With Keratoconjunctivitis Sicca
Conditions: Keratoconjunctivitis Sicca;   Dry Eye Syndrome
Intervention: Drug: dexamethasone, artificial tears
Outcome Measure: Changes in ocular surface measured by routine opthalmic dyes
4 Recruiting The Utility of in Vivo Confocal Microscopy to Assess Cellular Response and Efficacy of Long-term Topical Steroid Treatment in Patients With Dry Eye Disease
Condition: Dry Eye Disease
Interventions: Drug: Lotemax;   Drug: Artificial Tears
Outcome Measures: In Vivo Confocal Microscopy (IVCM): Superficial corneal epithelial cells: Density, size, and hypereflectivity;   In Vivo Confocal Microscopy: Corneal subbasal immune dendritiform cells: Density, size, and cell field;   In Vivo Confocal Microscopy: Corneal subbasal nerves: Number and length of the main nerves and the branches;   Ocular Signs: Corneal epitheliopathy;   Ocular Signs: Conjunctival epitheliopathy;   Ocular Signs: Tear Break Up Time (TBUT);   Ocular Signs: Schirmer's Test with Anesthesia;   Ocular Signs: Intraocular pressure (IOP) by measure of applanation tonometry;   Ocular Symptoms: Ocular Surface Disease Index (OSDI) questionnaire;   Ocular Symptoms: • Symptom Assessment iN Dry Eye (SANDE) questionnaire
5 Unknown  Low-Dose (17.5 mg/Day) Acitretin: Comparable Efficacy Without the Side Effects?
Condition: Psoriasis
Intervention: Drug: Acitretin 17.5 mg/day
Outcome Measures: Improvement in psoriasis;   Subjective efficacy/tolerability
6 Recruiting Effects of Magnetic Therapy and Seawater Combined in Decreasing Intraocular Presion.
Conditions: Primary Open Angle Glaucoma;   Hypertension Ocular
Interventions: Device: Pulsed Electromagnetic Field Therapy;   Drug: Seawater eyedrops
Outcome Measure: Intro-ocular pression after magnetic field exposition
7 Unknown  Proficiency of Eye Drop Instillation in Postoperative Cataract Patients in Ghana
Condition: Cataract Surgery
Intervention:
Outcome Measures: Instillation of one drop of Dexatrol into the eye;   Irritation or pain after surgery
8 Recruiting Using in Vivo Confocal Microscopy to Assess Cellular Response and Efficacy of Steroid Treatment in Dry Eye Disease
Condition: Dry Eye Syndrome
Interventions: Drug: loteprednol etabonate (Lotemax);   Drug: Soothe Tired Eyes Lubricant Eye Drop
Outcome Measure: To evaluate the efficacy of Lotemax as compared to Soothe Tired Eyes Lubricant Eye Drop , using clinical and in vivo confocal microscopic findings.
9 Recruiting Civamide Nasal Solution for Dry Eye
Condition: Dry Eye
Intervention: Drug: Civamide Nasal Spray
Outcome Measure: Schirmer Test
10 Recruiting Study to Investigate the Irritation Potential of GSK1940029 Gel
Condition: Acne Vulgaris
Interventions: Drug: 0.3% GSK1940029 gel;   Drug: 1% GSK1940029 gel;   Drug: 0.3%/1% vehicle gel only;   Other: Sterile distilled water;   Other: 0.5% SLS in sterile distilled water;   Other: 0.1% SLS in sterile distilled water;   Other: Patch only
Outcome Measures: Primary cutaneous irritation scores;   Cumulative cutaneous irritation scores;   Facial irritation scores;   Lanman-Maibach irritation classifications;   Tolerability of GSK1940029 as assessed by Clinical monitoring/observation;   Tolerability of GSK1940029 as assessed by adverse events (AEs);   Safety and tolerability of GSK1940029 as assessed by clinical laboratory tests;   Safety and tolerability of GSK1940029 as assessed by vital signs measurements;   Safety and tolerability of GSK1940029 as assessed by clinical monitoring/observation;   Ocular tolerability of topical applications of GSK1940029;   Plasma GSK1940029 pharmacokinetics (PK)
11 Recruiting A Randomized, Controlled, Double-masked, Clinical Trial of Autologous Serum Eye Drops for Severe Ocular Chronic Graft-versus-host Disease (GVHD) in Hematopoietic Stem Cell Transplant (HSCT) Patients
Condition: Graft vs Host Disease
Intervention: Drug: Autologous Serum Eye Drops
Outcome Measure: The primary outcome is the proportion of participants experiencing a & gt; = 50% reduction in the combined score of the modified Oxford punctate keratopathy grading and the NIH/NEI visual analogue scale in the study eye from baseline to Mont...
12 Recruiting The Natural History of Graft-Versus-Host Disease in the Eyes
Condition: Graft-Versus-Host Disease
Intervention:
Outcome Measures: The primary objective variable is ocular surface staining using fluorescein and lissamine green dyes. The primary subjective outcome measure is the OSDI;   Secondary outcome variables include changes in BCVA (ETDRS); tear film osmolarity; Schirmer's testing with anesthesia; meibomain gland function; tear break-up time.
13 Recruiting Phase II/III Study of the Efficacy and Safety of MacuCLEAR MC-1101 in Treating DryAge-Related Macular Degeneration
Condition: Non-Exudative Age Related Macular Degeneration
Interventions: Drug: MC-1101;   Drug: MC-1101 Vehicle
Outcome Measures: Visual Function;   Safety and tolerability (incidence and severity of adverse events, ocular irritability, ocular hyperemia)
14 Recruiting Demodex Blepharitis Treatment Study
Condition: Chronic Blepharitis
Interventions: Drug: Terpinen-4-ol;   Other: Placebo
Outcome Measures: Eradication of Demodex Mites;   Change in Lid Margin redness and Bulbar Conjunctival Hyperemia
15 Recruiting FID# 114657 in Contact Lens Wearers
Conditions: Refractive Error;   Symptoms of Ocular Dryness
Interventions: Drug: FID# 114657 eye drops (10 ml);   Drug: Saline eye drops (15 ml);   Device: Habitual contact lenses
Outcome Measures: Mean Pre-lens Tear Lipid Layer Thickness (LLT) after 2 hours of lens wear on Day 1;   Mean comfortable lens wear time (Time Uncomfortable - Time Insertion) at Baseline and Day 14;   Percentage of subjects that experience at least a unit increase from baseline score to Day 14 for overall comfort with lenses (1-10 scale);   Mean change from baseline in comfortable lens wear time (Time Uncomfortable - Time Insertion) to Day 14;   Mean Pre-lens Tear Lipid Layer Thickness after 2 hours of lens wear on Day 14
16 Unknown  Efficacy of the Chronic Application of Tear Formulations
Condition: Dry Eye
Interventions: Drug: Next Generation Emulsion;   Drug: Refresh Dry Eye Therapy;   Drug: Refresh Contacts
Outcome Measures: Tear Film Evaporation;   Interferometry;   Tear Film Osmolarity;   Non-invasive tear break up time;   Tear sampling and bio-marker analysis
17 Unknown  Chalazion Treatment Trial
Condition: Eyelid Chalazion
Interventions: Drug: Tobrex Drops and Ointment;   Drug: Tobradex Drops and Ointment;   Drug: Warm Compresses
Outcome Measure: Chalazion Size
18 Recruiting Observational Study to Evaluate and Compare the Rate and Extent of Inflammation After a Single Intravitreal Injection of Ranibizumab vs. a Single Intravitreal Injection of Aflibercept in Treatment Naive and Treatment Experienced Patients.
Condition: Neovascular Age Related Macular Degeneration
Intervention:
Outcome Measures: To evaluate post-intravitreal injection inflammatory response in patients receiving either ranibizumab or aflibercept.;   To evaluate patients 2-3 days post-injection for best corrected visual acuity
19 Recruiting Study to Evaluate the Safety, Tolerability and Pharmacokinetic of Single and 14 Day Repeat Topical Application of GSK1940029
Condition: Acne Vulgaris
Interventions: Drug: 0.3% GSK1940029 gel;   Drug: 1% GSK1940029 gel;   Drug: 0.3%/1% vehicle gel only
Outcome Measures: Safety of GSK1940029 as assessed by physical examination findings.;   Safety of GSK1940029 as assessed by vital signs;   Safety of GSK1940029 as assessed by 12-lead electrocardiogram (ECG);   Safety of GSK1940029 as assessed by dual lead telemetry;   Safety of GSK1940029 as assessed by hematology and chemistry parameters of clinical laboratory test;   Safety of GSK1940029 as assessed by urinalysis parameters of clinical laboratory test;   Safety of GSK1940029 as assessed by urine albumin:creatinine ratio (ACR);   Safety of GSK1940029 as assessed by adverse events;   Plasma GSK1940029 pharmacokinetics (PK);   Ocular tolerability of topical applications of GSK1940029
20 Recruiting Observational Study to Evaluate and Compare the Rate and Extent of Inflammation After a Single Injection of Ranibizumab vs. a Single Intravitreal Injection of Aflibercept in Treatment Naive and Treatment Experienced Patients
Condition: Age Related Macular Degeneration
Intervention:
Outcome Measures: To evaluate post-intravitreal injection inflammatory response in patients receiving either ranibizumab or aflibercept.;   To evaluate patients 2-3 days post-injection for best corrected visual acuity

These studies may lead to new treatments and are adding insight into 3% HYDROGEN PEROXIDE etiology and treatment.

A major focus of 3% HYDROGEN PEROXIDE research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss 3% HYDROGEN PEROXIDE